Skip to main content

Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Dr. Kamel Khalili and Lewis Katz School of Medicine Team Will Lead Project Evaluating Medication’s Effect on Coronaviruses

View All News

Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology and the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), will lead a project at LKSOM evaluating the medication Piclidenoson and its effect on the viral load of coronaviruses in a mammalian cell model system. Piclidenoson is currently undergoing a Phase III clinical trial to treat rheumatoid arthritis. It has previously demonstrated anti-viral activity against HIV, which is a single-stranded RNA virus – as are coronaviruses. Pharmaceutical Technology covered the news.